1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
SWS Hemodialysis Care Co., Ltd. Class A

SWS Hemodialysis Care Co., Ltd. Class A

SSSE:688410
10.33
CNY
+0.83
(+8.74%)
4.59BMarket Cap
Oct 28Next Earn
SWS Hemodialysis Care Co., Ltd. Class A
SSE:688410
(Shanghai Stock Exchange)

Recent

price

10.33

P/E

ratio

- -

div

yld

0.00%

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.82
0.24
0.37
0.3
0.38
0.48
0.83
0.84
0.85
1.53
1.27
1.81
- -
Revenue per Share
-0.08
0.01
0.02
-0.01
-0.09
-0.11
0.07
0.06
0.13
0.43
0.16
0.33
- -
Basic EPS, GAAP
-0.08
-0.04
-0.15
-0.24
-0.22
-0.13
-0.14
0.01
0.52
-0.11
0.13
0.34
- -
Free Cash Flow per Basic Share
0.03
- -
- -
- -
- -
- -
0.01
0.01
- -
0.06
0.1
0.07
- -
Dividend per Share
0.28
0.28
0.3
0.66
0.54
0.42
1.08
1.15
3.37
3.77
3.75
3.98
4.05
Book Value per Share
0.25
0.26
0.27
0.64
0.51
0.39
1.04
1.07
3.31
3.5
3.5
3.71
3.78
Tangible Book Value per Share
47
239
236
284
299
299
306
337
450
450
448
445
446
Basic Weighted Avg Shares
38
57
87
85
114
142
254
283
382
690
567
807
- -
Sales/Revenue/Turnover
-26.01
-8.68
-1.69
-5.71
-22.86
-23.37
9.99
10.16
16.93
27.83
10.73
22.7
- -
Operating Margin (%)
3
3
3
4
8
10
12
17
17
19
22
22
- -
Depreciation Expense
-4
2
5
-4
-27
-34
21
19
59
194
71
146
- -
Net Income, GAAP
- -
- -
5.48
- -
- -
- -
12.77
17.73
10.19
12.61
6.46
12.45
- -
Effective Tax Rate (%)
-9.84
2.68
5.23
-4.27
-23.77
-23.89
8.1
6.87
15.51
28.18
12.5
18.08
- -
Profit Margin (%)
77
72
55
154
104
71
291
314
1,440
1,534
1,446
1,391
1,243
Working Capital
- -
- -
- -
22
20
34
32
20
9
4
1
1
1
LT Debt
83
85
89
206
168
133
369
389
1,515
1,696
1,678
1,779
1,811
Total Equity
- -
- -
-2.09
- -
- -
- -
5.68
5.21
5.68
11.72
4.41
9.25
- -
Return on Invested Capital (%)
- -
- -
4.72
- -
- -
- -
7.75
4.9
6.36
12.16
4.61
8.54
- -
Return on Capital (%)
- -
1.83
5.26
-2.54
-15.07
-23.67
8.39
5.18
6.23
12.11
4.19
8.42
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
447
447
447
Market Capitalization
4,784
4,804
4,589

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,848
1,799
1,772
Cash, Cash Equivalents & STI
1,514
1,452
1,413
Accounts Receivable, Net
112
115
124
Inventories
185
192
187
Total Current Liabilities
457
437
529
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
58.68%
62.31%
6%
Free Cash Flow
485.93%
913.29%
153.24%
Net Income, GAAP
99.24%
93.85%
105.8%
Sales/Revenue/Turnover
33.83%
30.26%
42.24%
Total Cash Common Dividend
429.89%
747.41%
-25.89%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
162
115
140
149
567
2025
189
168
- -
223
807
2026
230
234
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.03
0.04
0.02
0.16
2025
0.08
0.04
- -
0.09
0.33
2026
0.12
0.09
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.1
2025
- -
- -
- -
- -
0.07
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
SWS Hemodialysis Care Co., Ltd. is a China-based medical device and healthcare enterprise primarily engaged in the research, development, manufacture, and commercialization of blood purification equipment, disposable consumables, and renal healthcare services. Founded in 2001 and headquartered in Chongqing, China, the company operates through three integrated business segments: Blood Purification Equipment, Consumables, and Dialysis Medical Services. Its equipment offerings include hemodialysis machines for chronic renal replacement therapy; continuous renal replacement therapy and continuous blood purification systems for acute kidney injury and critical care; hemoperfusion devices; plasma exchange and artificial liver support systems; and centralized reverse-osmosis water treatment systems. The company manufactures a broad array of consumables, including high-flux and low-flux hollow-fiber dialyzers; bilirubin adsorption and hemoperfusion cartridges; extracorporeal blood circuit tubing sets for hemodialysis and continuous renal replacement therapy; disposable arteriovenous fistula needles; and dialysis dry powders and liquid concentrates. Additionally, SWS Hemodialysis Care operates specialized chain hemodialysis clinics and provides proprietary digital dialysis information management systems that enable real-time patient data tracking and treatment automation. The company serves public and private hospitals, intensive care units, emergency departments, and outpatient dialysis centers across China as well as international markets across Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. In recent developments, the company has expanded its manufacturing capacity through the commissioning of automated high-flux dialyzer production lines; broadened its international market footprint through updated global regulatory clearances and overseas distribution agreements; launched next-generation intelligent continuous renal replacement therapy platforms equipped with cloud connectivity and precision fluid-balance controls; and formed strategic clinical partnerships with domestic medical institutions to advance pediatric renal replacement therapies and multi-organ blood purification protocols.